Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

Objective: The objective of this study was tocompare 1-year total healthcare costs for patientswith overactive bladder (OAB) initiating treatmentwith extended-release formulations of tolterodineand ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The novel muscarinic M3 receptor antagonist DA8010 ...

NORTHBROOK, Ill., June 28, 2012 -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug ...

The approval was based on data from the pivotal phase 3 EMPOWUR study. The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron; Urovant Sciences) for the treatment of overactive ...

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz TM (fesoterodine fumarate) extended release tablets and the YourWay TM plan (www.ToviazYourWay.com), a comprehensive, customizable ...

Study authors developed a Markov model with health states based on daily urinary incontinence episodes (UIEs) to compare the cost-effectiveness of onabotulinumtoxinA, implantable sacral nerve ...

Prostate cancer survivorship research focuses largely on oncological outcome; however, fewer studies are available that assess the effects of prostate cancer and its treatment on bladder function.

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign Holly Robinson Peete ...